Keen Vision Acquisition Corporation to Merge with Medera Inc. (NASDAQ Listing)

Welltower (Affiliate) to Acquire NorthStar Healthcare Income; TPG to Acquire Altus Power; Jade Biosciences to Merge with Aerovate Therapeutics (Plus KVAC/ Madera SPAC Merger)

March 18, 2025

Healthcare Services

The announcement flags multiple pending M&A actions in which NorthStar Healthcare Income is proposed to be acquired by an affiliate of Welltower for $3.03 per share in cash, Altus Power is proposed to be acquired by TPG for $5.00 per share in an all-cash deal, and Aerovate Therapeutics is proposed to merge with Jade Biosciences. It also references Keen Vision Acquisition Corp. in connection with a proposed merger with Madera Inc.

Accel-KKR Acquires VisiQuate

October 1, 2024

Cloud & SaaS

Accel-KKR, a technology-focused private equity firm, has acquired VisiQuate, a Santa Rosa-based provider of revenue cycle analytics and AI-powered workflow automation for health systems. The partnership is intended to accelerate VisiQuate’s product innovation, expand its team, and drive growth across healthcare provider customers.

Graf Acquisition Corp. IV Completes Business Combination with NKGen Biotech

October 2, 2023

Biotechnology

Graf Acquisition Corp. IV completed its previously announced business combination with NKGen Biotech, Inc., resulting in NKGen becoming a wholly‑owned subsidiary and the combined company listing on Nasdaq under the ticker NKGN. The transaction provides NKGen with access to public markets and capital to accelerate development and commercialization of its autologous, allogeneic and CAR‑NK cell therapy programs.

Viveon Health Acquisition Corp. to Merge with Suneva Medical

January 12, 2022

Medical Devices

Suneva Medical, a San Diego–based regenerative aesthetics medical technology company, has entered into a definitive merger agreement with special purpose acquisition company Viveon Health Acquisition Corp. The transaction will combine Suneva with the public SPAC vehicle (NYSE American: VHAQ) to provide growth capital and public-market access for Suneva, with the combined company expected to trade on the NYSE under the symbol "RNEW."

Chardan Healthcare Acquisition 2 Corp. Completes Business Combination with Renovacor, Inc.

September 2, 2021

Biotechnology

Renovacor, an early‑stage biotechnology company developing AAV‑based gene therapies for BAG3‑associated cardiovascular and CNS diseases, closed a business combination with special purpose acquisition company Chardan Healthcare Acquisition 2 Corp. (CHAQ) and will begin trading on the New York Stock Exchange as Renovacor, Inc., with approximately $95.1 million of gross proceeds (including a $30.0 million PIPE) to fund clinical development into 2023. The transaction preserves Renovacor’s existing management team and provides public-market access and capital to advance its lead program, REN‑001, toward IND submission and a Phase I/II trial.

Novartis Acquires Vedere Bio

September 30, 2020

Biotechnology

Novartis has acquired Vedere Bio, a Cambridge-based optogenetics AAV gene therapy company, for $150 million upfront plus up to $130 million in potential regulatory and clinical milestones (total consideration of $280 million). The deal includes Vedere Bio's lead preclinical intravitreal AAV programs focused on pan-genotypic vision restoration; earlier-stage assets were spun out into a newly formed independent company, Vedere Bio II.